

Test Definition: GBACS

Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody, Cell-Binding Assay, Serum

Overview

Useful For

Evaluating patients with suspected autoimmune encephalitis and autoimmune epilepsy using serum specimens

Method Name Cell-Binding Assay (CBA)

NY State Available Yes

Specimen

Specimen Type Serum

Supplies: Sarstedt Aliquot Tube, 5 mL (T914) Collection Container/Tube: Preferred: Red top Acceptable: Serum gel Submission Container/Tube: Plastic vial Specimen Volume: 0.3 mL Collection Instructions: Centrifuge and aliquot serum into a plastic vial.

Forms

<u>If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request</u> (T732) with the specimen.

Specimen Minimum Volume 0.25 mL

Reject Due To

| Gross hemolysis | Reject |
|--------------------|--------|
| Gross lipemia | Reject |
| Gross icterus | Reject |

Specimen Stability Information



Test Definition: GBACS

Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody, Cell-Binding Assay, Serum

| Specimen Type | Temperature | Time | Special Container |
|---------------|--------------------------|----------|-------------------|
| Serum | Refrigerated (preferred) | 28 days | |
| | Ambient | 72 hours | |
| | Frozen | 28 days | |

Clinical & Interpretive

Clinical Information

Gamma-amino butyric acid type A (GABA-A) receptor autoantibodies are highly predictive of GABA-A receptor autoimmune encephalitis. Patients who are seropositive for GABA-A receptor encephalitis have characteristic clinical-radiologic presentations including frequent seizures and multifocal lesions in the white matter. Majority of patients are treatable with immunotherapy.

Reference Values

Negative

Interpretation

Seropositivity for gamma-amino butyric acid type A receptor autoantibodies supports the clinical diagnosis of autoimmune encephalitis with neurological presentations including seizures and multifocal lesions in the white matter. A search for thymoma cancer and a trial of immunotherapy should be considered.

Cautions

Negative results do not exclude the diagnosis of autoimmune encephalitis. Only 2% of autoimmune encephalitis cases are associated with autoantibodies against gamma-amino butyric acid type A receptor.

Clinical Reference

1. O'Connor K, Waters P, Komorowski L, et al. GABAA receptor autoimmunity A multicenter experience. Neurol Neuroimmunol Neuroinflamm 2019;6(3):e552. doi:10.1212/NXI.000000000000552

2. Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017;88(11):1012-1020. doi:10.1212/WNL.000000000003713

3. Waters P, Irani S. GABA-A receptor antibodies and their clinical associations. Neurology. 2017; 88:1010-1011 4. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276-286

Performance

Method Description

Patient specimen is applied to a composite slide containing transfected and nontransfected EU90 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG



Test Definition: GBACS

Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody, Cell-Binding Assay, Serum

binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN, FA_112d-1_A_UK_C13, 02/25/2019)

PDF Report

No

Day(s) Performed Monday through Sunday

Report Available 5 to 10 days

Specimen Retention Time 28 days

Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

Fees & Codes

Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86255

LOINC[®] Information

| Test ID | Test Order Name | Order LOINC [®] Value |
|---------|--------------------|--------------------------------|
| GBACS | GABA-A-R Ab CBA, S | 101874-6 |

| Result ID | Test Result Name | Result LOINC [®] Value |
|-----------|--------------------|---------------------------------|
| 620232 | GABA-A-R Ab CBA, S | 101874-6 |